A Chinese-developed sequencing assay using donor-derived cell-free DNA reported a threshold for detecting acute heart transplant rejection, enabling noninvasive monitoring that could reduce reliance on routine biopsies. The first prospective study identified a 0.33% threshold, positioning the approach as a more scalable surveillance option for transplant programs. The result matters for biotech and clinical diagnostics because it translates ctDNA fraction measurement into an actionable cut-off—an element that often determines whether cfDNA assays can be integrated into protocols rather than remaining research tools. As transplant programs expand, cell-free DNA could become a practical complement to imaging and endomyocardial biopsy, with the strongest near-term impact likely in settings where biopsy scheduling and throughput are limiting.